Efficacy and Safety of MP-424, Peginterferon Alfa-2b and Ribavirin in Chronic Hepatitis C Who Have Not Achieved an Undetectable HCV RNA Level With Previous Interferon Based Therapy
3期
已完成
NCT00781274
| 适应症 | Hepatitis C |
|---|
| 分期 | 3期 |
|---|
| 申办方 | Tanabe Pharma Corporation |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 32 人 |
|---|
| 干预（药物） | MP-424, Ribavirin, Peginterferon Alfa-2b |
|---|
| 开始日期 | 2008年12月 |
|---|
| 完成日期 | 2010年7月 |
|---|
| 结果公布日 | 2012年8月20日 |
|---|
摘要
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b and RBV in patients with (Genotype 1) hepatitis C, who did not respond to previous treatment.
The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)
After 24 weeks of follow-up · percentage of subjects achieving SVR
| MP-424 | 34.4 percentage of subjects achieving SVR |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。